Jennison Associates LLC Has $83.50 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Jennison Associates LLC raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 309,219 shares of the biopharmaceutical company's stock after purchasing an additional 49,306 shares during the period. Jennison Associates LLC owned about 0.24% of Alnylam Pharmaceuticals worth $83,495,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in ALNY. Capital World Investors lifted its holdings in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after purchasing an additional 92,101 shares during the period. Vanguard Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock worth $2,996,296,000 after purchasing an additional 98,303 shares during the period. Capital Research Global Investors lifted its holdings in Alnylam Pharmaceuticals by 32.9% in the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after purchasing an additional 1,724,610 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in Alnylam Pharmaceuticals by 39.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after purchasing an additional 1,245,195 shares during the period. Finally, Norges Bank acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $577,941,000. Institutional investors own 92.97% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Bank of America boosted their price target on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a "buy" rating in a research report on Friday, July 11th. Morgan Stanley dropped their price target on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research report on Friday, April 11th. Jefferies Financial Group boosted their price target on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a research report on Monday, July 7th. Scotiabank boosted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 31st. Finally, Wall Street Zen upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-three have issued a buy rating to the company's stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $347.75.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the sale, the chief executive officer directly owned 48,948 shares of the company's stock, valued at approximately $14,978,088. This represents a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.20% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Up 1.5%

NASDAQ:ALNY traded up $4.76 during mid-day trading on Tuesday, reaching $325.28. The stock had a trading volume of 1,268,974 shares, compared to its average volume of 854,899. The business's 50 day moving average is $308.63 and its 200 day moving average is $273.02. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $333.70. The stock has a market cap of $42.41 billion, a P/E ratio of -155.64 and a beta of 0.23. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The company's quarterly revenue was up 20.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.16) EPS. As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.